Target intelligence / Profile preview

Transcription factor AP-2 gamma (TFAP2C)

Target
TFAP2C
Molecular classification
Transcription factor
01

Overview

Transcription factor AP-2 gamma is a DNA-binding transcription factor, encoded by the gene TFAP2C, and is a member of the AP-2 family. It regulates gene expression by binding to specific enhancer DNA sequences (5'-GCCNNNGGC-3') and can function as a homodimer or heterodimer with other AP-2 family members. TFAP2C plays a crucial role during early embryogenesis, particularly in morphogenesis and the development of multiple tissues, notably the placenta, eyes, facial structures, and neural tube. It acts as both an activator and repressor of gene expression, activating genes essential for differentiation and repressing others such as MYC and CD44. Dysregulation or mutation can lead to developmental syndromes (e.g., branchiooculofacial syndrome) or contribute to tumorigenesis, particularly in breast cancer, where it is known to regulate estrogen receptor pathways and serve as a biomarker of tumor subtype and prognosis[1][2][4].

Other names
AP2-gammaAP2-GAMMAERF1TFAP2GhAP-2gActivating enhancer-binding protein 2 gammaTranscription factor ERF-1Estrogen receptor factor 1
02

Mechanism of action

Modulation of transcriptional activity via DNA binding and interaction with enhancer elements. Regulation of downstream genes implicated in tumor progression and embryogenesis.

03

Biological functions

Regulation of gene transcriptionEmbryonic development (including morphogenesis)Regulation of placenta developmentRetinoic acid-mediated differentiation (eyes, face, body wall, limbs, neural tube)Control of cell proliferation and differentiation
04

Disease associations

Cancer (notably breast and prostate cancer)Branchiooculofacial syndromeEmbryonic/fetal developmental disordersOther malignancies associated with AP-2 transcription factor dysregulation
05

Safety considerations

Potential risk of embryo/fetal developmental defects with inhibitionBroad regulatory activity suggests risk of widespread off-target effects
06

Biomarkers

CD44 (downregulation as biomarker in some cancers)TFAP2C expression (prognostic in breast cancer)

Beyond the preview

Go deeper on Transcription factor AP-2 gamma (TFAP2C).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Transcription factor AP-2 gamma (TFAP2C).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call